I am an attending physician in both the Blood and Marrow Transplantation and the Hematologic Malignancies sections. In addition to caring for patients, I am also interested in finding ways to stimulate the immune system to treat pediatric leukemias.
My research is in the development of a controlled method of immune stimulation that allows the body’s own immune defense system to recognize and kill leukemia cells. Some patients whose leukemia does not respond to chemotherapy go into remission following an infection. We certainly try hard to protect children from infection during cancer therapy; however, those children who develop infections and then go on to have spontaneous remissions are sending us an important message about how powerful the immune system can be in treating leukemia.
Immune stimulation may help children with chemotherapy-resistant leukemia and improve the effectiveness of current treatments without adding long-lasting toxicity. Furthermore, if we stimulate a child’s immune system to recognize leukemia, long-term immune memory may act like a vaccine, recognizing leukemia cells and preventing relapse for his or her lifespan. We are working with a national group to bring these treatments into clinical trials and continue to look for new ways to help the immune system fight leukemia.
While research is a very important and fulfilling part of my job, the reason I became a doctor is to help care for sick children. A cancer diagnosis turns a family’s world upside down and comes with a flood of new information that can feel overwhelming. I believe in open, honest communication with patients and parents, including being clear about when we don’t know the answers, what we can do to find out, and that we are here to support families through every step of the way. What I love most about working at CHOP are the interactions between patients, families, and staff – we work together to give our children the best possible care. We also have the tremendous privilege of working side-by-side with the world’s leaders in nearly every pediatric specialty.
I am fortunate to be a part of two wonderful subspecialty teams within Oncology. The Hematologic Malignancies (leukemia and lymphoma) and Transplant teams meet weekly to discuss every currently active patient to ensure that each child in our care has the benefit of many eyes, ears and minds. We are always thinking about ways we can improve patient care. CHOP is a very special place where state-of-the-art research meets comprehensive, family-centered patient care, and I’m proud to be a part of it.
- Education and Training
MD - Oregon Health Sciences University, Portland, OR
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA
Pediatric Hematology-Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA
MPH in Epidemiology and Biostatistics - Oregon Health Sciences University, Portland, OR
MA in Linguistics - McGill University, Montréal, Quebec, Canada
- Titles and Academic Titles
Assistant Professor, Perelman School of Medicine at the University of Pennsylvania
- Departments and Services
Wilkes JJ, Hennessy S, Xiao R, Rheingold S, Seif A, Huang YSV, Vendetti N, Li Y, Bagatell R, Aplenc R, Fisher B: Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL). American Society of Hematology 2014.
Seif AE, Jo S, Altman J, Bassiri H, Barrett DM, Grupp SA, Reid GSD: Epitope spreading Is required for long-term protection against acute lymphoblastic leukemia. American Society of Hematology 2014.
Rao P, Li Y, Alonzo TA, Sung L, Gerbing RB, Getz KD, Seif AE, Miller TP, Huang YS, Bagatell R, Hall M, Fisher BT, Gamis AS, Aplenc R: Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Children's Oncology Group. American Society of Hematology 2014.
Goodman EK, Li Y, Fisher BT, Fitzgerald J, Seif AE, Huang YS, Bagatell R, Aplenc R: Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. American Society of Hematology 2014.
Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Bagatell R, Fisher BT, Aplenc R: Comparison of Resource Utilization in Children Discharged Versus Children That Remain Hospitalized Following Chemotherapy for Acute Myeloid Leukemia. American Society of Hematology 2014.
DiNofia A*, Seif AE*, Devidas M, Li Y, Hall M, Huang YSV, Bagatell R, Carroll WL, Winick N, Hunger SP, Fisher BT, Larsen EC, Aplenc R.: Resource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. American Society of Hematology 2014.
Teachey DT, Vincent T, Smith-Whitley K, Lambert M, Seif A, Grupp SA: Targeting mTOR signaling leads to complete and durable responses in children with multi-lineage autoimmune cytopenias, including ALPS, SLE, EVANS and CVID. American Society of Hematology Annual Meeting 2013.
Seif AE, Barrett DM, Grupp SA, Reid GSD: Innate and adaptive immune control of neoantigen-bearing acute lymphoblastic leukemia (ALL) enhanced by epitope spread. AACR Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes 2013.
Seif AE, Barrett DM, Grupp SA, Reid GSD: Innate and adaptive immune control of neoantigen-bearing acute lymphoblastic leukemia (ALL) enhanced by epitope spread. Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcome 2013.
Oikonomopoulou Z, Gousis C, Patel R, Klieger SB, Kajon A, Seif A, Fisher BT: Infection Rate after Stem Cell Transplantation for Hemophagocytic Lymphohistiocytosis in Children Receiving Hematopoietic Stem Cell Transplantation. Infectious Disease Society of America, Annual Meeting, San Francisco, CA 2013.
Lee G, Fisher BT, Huang YS, Li Y, Seif A, Xiao R, Aplenc R.: Epidemiology of Influenza Hospitalizations in Children with Acute Lymphoblastic Leukemia (ALL), 1999 to 2011. Infectious Disease Society of America, Annual Meeting, San Francisco, CA 2013.
Fisher BT, Sammons JS, Klieger S, Leckerman K, Seif AE, Li Y, Huang YSV, Torp K, Harris T, Rheam D, Shah A, Aplenc R.: Variation in Risk of Clostridium difficile infection across beta-lactam antibiotics in children with new onset acute lymphoblastic leukemia European Society for Paediatric Infectious Diseases 31st Annual Meeting, Milan Italy 2013.
Fisher BT, Aplenc R, Kavcic M, Li Y, Seif AE, Bagatell R, Huang YS, Zaoutis T, Torp K, Leckerman K.: Antifungal Prophylaxis Associated with Decreased Induction Mortality Rates in Children with New Onset Acute Myeloid Leukemia. Infectious Disease Society of America, Annual Meeting, San Francisco, CA 2013.
Fidanza M, Jo S, Grupp SA, Seif AE, Reid GSD: Toll-like receptor ligands delay acute leukemia onset via depletion of pre-leukemic cells. AACR Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcome 2013.
Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R: Comparison of Administrative/Billing Data to Expected Protocol-Mandated Chemotherapy Exposure in Children with Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Pediatric Blood & Cancer 2015 Notes: doi: 10.1002/pbc.25475. [Epub ahead of print]
Lee GE, Fisher BT, Xiao R, Coffin SE, Feemster K, Seif AE, Bagatell R, Li Y, Huang YSV, Aplenc R: Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society Page: 1-7, 2014 Notes: (epub). DOI:10.1093/jpids/piu066.
Goodman Elizabeth K, Reilly Anne F, Fisher Brian T, Fitzgerald Julie, Li Yimei, Seif Alix E, Huang Yuan-Shung, Bagatell Rochelle, Aplenc Richard: Association of Weekend Admission With Hospital Length of Stay, Time to Chemotherapy, and Risk for Respiratory Failure in Pediatric Patients With Newly Diagnosed Leukemia at Freestanding US Children's Hospitals. JAMA pediatrics 168(10): 925-31, Aug 2014 Notes: doi: 10.1001/jamapediatrics.2014.1023.
Desai Ami V, Kavcic Marko, Huang Yuan-Shung, Herbst Nicole, Fisher Brian T, Seif Alix E, Li Yimei, Hennessy Sean, Aplenc Richard, Bagatell Rochelle: Establishing a high-risk neuroblastoma cohort using the Pediatric Health Information System Database. Pediatric blood & cancer 61(6): 1129-31, Jun 2014.
Seif Alix E, Fisher Brian T, Li Yimei, Torp Kari, Rheam Douglas P, Huang Yuan-Shung V, Harris Tracey, Shah Ami, Hall Matthew, Fieldston Evan S, Kavcic Marko, Vujkovic Marijana, Bailey L Charles, Kersun Leslie S, Reilly Anne F, Rheingold Susan R, Walker Dana M, Aplenc Richard: Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatric blood & cancer 61(5): 846-52, May 2014. PMCID: PMC3951664
Seif Alix E,* Walker Dana M,* Li Yimei, Huang Yuan-Shung V, Kavcic Marko, Torp Kari, Bagatell Rochelle, Fisher Brian T, Aplenc Richard: Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatric blood & cancer Page: doi: 10.1002/pbc.25043. [Epub ahead of print] Mar 2014.
Maude Shannon L, Fitzgerald Julie C, Fisher Brian T, Li Yimei, Huang Yuan-Shung, Torp Kari, Seif Alix E, Kavcic Marko, Walker Dana M, Leckerman Kateri H, Kilbaugh Todd J, Rheingold Susan R, Sung Lillian, Zaoutis Theoklis E, Berg Robert A, Nadkarni Vinay M, Thomas Neal J, Aplenc Richard: Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 15(2): 112-20, Feb 2014.
Fisher Brian T, Kavcic Marko, Li Yimei, Seif Alix E, Bagatell Rochelle, Huang Yuan-Shung, Zaoutis Theoklis, Torp Kari, Leckerman Kateri H, Aplenc Richard: Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 58(4): 502-8, Feb 2014. PMCID: PMC3905759
Fisher Brian T, Singh Sonia, Huang Yuan-Shung, Li Yimei, Gregory John, Walker Dana, Seif Alix E, Kavcic Marko, Aplenc Richard: Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. Pediatric blood & cancer 61(1): 68-73, Jan 2014. PMCID: PMC3927454
Fisher Brian T, Harris Tracey, Torp Kari, Seif Alix E, Shah Ami, Huang Yuan-Shung V, Bailey L Charles, Kersun Leslie S, Reilly Anne F, Rheingold Susan R, Walker Dana, Li Yimei, Aplenc Richard: Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data. Medical care 52(1): e1-6, Jan 2014. PMCID: PMC3381055
Lothstein Katherine, Fisher Brian, Li Yimei, Seif Alix, Harris Tracey, Torp Kari, Kavcic Marko, Huang Yuan-Shung V, Rheingold Susan R, Aplenc Richard: Zoonotic infections in pediatric patients with acute leukemia. Pediatric blood & cancer 60(12): E160-2, Dec 2013. PMCID: PMC3915061
Fisher Brian T, Gerber Jeffrey S, Leckerman Kateri H, Seif Alix E, Huang Yuan-Shung V, Li Yimei, Harris Tracey, Torp Kari, Douglas Rheam, Shah Ami, Walker Dana, Aplenc Richard: Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. Leukemia & lymphoma 54(8): 1633-9, Aug 2013. PMCID: PMC3906846
Seif A E, Naranjo A, Baker D L, Bunin N J, Kletzel M, Kretschmar C S, Maris J M, McGrady P W, von Allmen D, Cohn S L, London W B, Park J R, Diller L R, Grupp S A: A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone marrow transplantation 48(7): 947-52, Jul 2013. PMCID: PMC3638062
Teachey David T, Rheingold Susan R, Maude Shannon L, Zugmaier Gerhard, Barrett David M, Seif Alix E, Nichols Kim E, Suppa Erica K, Kalos Michael, Berg Robert A, Fitzgerald Julie C, Aplenc Richard, Gore Lia, Grupp Stephan A: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121(26): 5154-7, Jun 2013. PMCID: PMC4123427
Kavcic Marko, Fisher Brian T, Seif Alix E, Li Yimei, Huang Yuan-Shung, Walker Dana, Aplenc Richard: Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. The Journal of Pediatrics 162(6): 1252-8, 1258.e1, Jun 2013. PMCID: PMC3909336
Kavcic Marko, Fisher Brian T, Li Yimei, Seif Alix E, Torp Kari, Walker Dana M, Huang Yuan-Shung, Lee Grace E, Tasian Sarah K, Vujkovic Marijana, Bagatell Rochelle, Aplenc Richard: Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. Cancer 119(10): 1916-23, May 2013. PMCID: PMC3648620
Walker Dana M, Fisher Brian T, Seif Alix E, Huang Yuan-Shung V, Torp Kari, Li Yimei, Aplenc Richard: Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatric blood & cancer 60(4): 616-20, Apr 2013. PMCID: PMC3918414
Kavcic Marko, Fisher Brian T, Torp Kari, Li Yimei, Huang Yuan-Shung, Seif Alix E, Vujkovic Marijana, Aplenc Richard: Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database. Pediatric blood & cancer 60(3): 508-11, Mar 2013. PMCID: PMC3684426
Posters and Presentations
Seif AE, Jo S, Barrett DM, Grupp SA, Reid GSD: Recognition of Multiple Tumor Antigens is required for Durable Immune Control of Acute Lymphoblastic Leukemia. First Annual Immuno-Oncology Young Investigators' Forum 2015 Notes: oral presentation.
"Summon up the blood: generating durable immunity to acute lymphoblastic leukemia", Division of Pediatric Hematology and Oncology, Vanderbilt University, Nashville, TN, October 2014.
"Immunology of Relapse after Transplant for ALL", Children's Oncology Group breakout session: SCT in ALL, Dallas, TX, September 2014.
"Allogeneic stem cell transplantation in children with acute lymphoblastic leukemia", OPTUMHealth: Advances in the Management of Oncology, Stem Cell and Solid Organ Transplant Patients, San Diego, CA, May 2014.
"Paging Dr. Coley: Approaches to breaking immune tolerance to acute lymphoblastic leukemia", Division of Pediatric Hematology and Oncology, University Hospitals - Rainbow Babies and Children's Hospital, Cleveland, OH, November 2013.
"Stem Cell Transplantation for Pediatric Solid Tumors", OPTUMHealth: Advances in the Management of Oncology, Stem Cell and Solid Organ Transplant Patients, Scottsdale, AZ, April 2013.
- Awards and Honors
2010, Canuso Foundation Innovation Award
2010, American Society for Blood and Marrow Transplantation/Robert A. Good New Investigator Award
2009, American Society of Pediatric Hematology/Oncology Young Investigator Award
2008, Joseph E. Stokes, Jr. Research Institute Excellence in Translational Research Award
2008, American Society of Pediatric Hematology/Oncology Young Investigator Travel Award
2006, American Association of Immunologists Introductory Course Scholarship Award
2005, Children's Hospital of Philadelphia Anne E. Dyson Advocacy Award
2005, Children's Hospital of Philadelphia Resident Humanitarian Award
2002, Alpha Omega Alpha Honor Society
2000, American Heart Association Student Scholar in Cardiovascular Disease & Stroke
2000, N.L. Tartar Trust Fellow
1999-2000, Oregon Health Sciences University Laurel Scholar
1992, McGill University - University Scholar
1990-1991, McGill University - University Scholar
- Editorial and Academic Positions
Ad hoc reviewer
2014-present, Bone Marrow Transplantation
2014-present, Anti-Cancer Drugs
2014-present, Journal of Hospital Medicine
2013, CDC/NCEH/ATSDR Final Reports Publications
2013-present, Pediatric Blood & Cancer
2008-present, Biology of Blood and Marrow Transplantation
2015-present, Infectious Diseases Fellowship Oversight Committee
2015-present, Division of Oncology & Center for Childhood Research Strategic Planning Process Steering Committee
2011-present, Clinical Research Quality Assurance Committee, Center for Childhood Cancer Research
2009-present, Pediatric Protocol Review Committee, Center for Childhood Cancer Research
2009-present, Leukemia & Lymphoma Clinical Committee, Division of Oncology
2008-present, Blood and Marrow Transplantation Clinical Committee, Division of Oncology
Memberships in Professional Organizations
2006-present, American Association for Cancer Research
2006-present, American Society for Blood and Marrow Transplantation
2006-present, American Society of Clinical Oncology
2006-present, American Society of Hematology
2006-present, American Society of Pediatric Hematology/Oncology
- Awards and Honors